health

Johnson & Johnson COVID-19 vaccine produces strong immune response in early trial

6 Comments
By Vishwadha Chander

The requested article has expired, and is no longer available. Any related articles, and user comments are shown below.

© Thomson Reuters 2020.

©2024 GPlusMedia Inc.

6 Comments
Login to comment

Fingers crossed.

3 ( +3 / -0 )

Sorry, 50-100 trillion virions, still a very low dose under a microgram.

2 ( +3 / -1 )

It is a nice touch to directly put the link to the manuscript on the article. The tests are obviously not complete and require more participants being followed for longer time, but the activation of both humoral and cellular immunity seems to be extremely good.

From the manuscript, a dose equivalent to 1e10 (10 trillion) viruses seems high but it is actually a really low amount, equivalent to less than one microgram of protein, it is surprising that such strong effects can be observed with such a little amount and that is a very positive finding because it means production can be faster and cheaper, and possible negative side effects minimized much more easily.

1 ( +2 / -1 )

So please just tell us: will the vaccine be effective and when can the public get it?

Unfortunately that is something that requires time and completing the full clinical trials to be known.

At this time what we know is that the vaccine, even in tiny doses, produce very strong immunity in the two principal ways we have to measure, immunity that depends on antibodies (that may be short term) and immunity that depends on cells (that apparently works for much longer against highly pathogenic coronaviruses). We also know that up until now there is not dangerous side effects in the people that have been vaccinated.

What we still need to know and that requires more tests is to see if the immunity measured actually means the people is protected against infection and that the vaccinated people have no negative reactions when they get the real infection. It is very unusual but for some diseases having good cellular and antibody immunity is not enough and people can get sick or even have dangerous reactions after the infection.

For this kind of vaccine what is left to do is the phase III clinical trials that take at least 6 months to be completed. So it would be ready for April 2021 at the soonest, as long as everything keeps going well.

1 ( +2 / -1 )

@Virusex

Thanks for your information but I guess that 99% of the posters here are no medical experts, including me, and we don't understand your information.

I guess you are a scientist or medical expert.

So please just tell us: will the vaccine be effective and when can the public get it?

0 ( +2 / -2 )

Login to leave a comment

Facebook users

Use your Facebook account to login or register with JapanToday. By doing so, you will also receive an email inviting you to receive our news alerts.

Facebook Connect

Login with your JapanToday account

User registration

Articles, Offers & Useful Resources

A mix of what's trending on our other sites